Release not found

Name: PPN World global press-release archive
License: https://www.ppnworld.com/legal/press-content

This press release isn’t in the live store anymore. Open the original on the wire, or jump into the live feed.

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) · Novartis · PPN World